glp 1 agents GLP-1 Agonists Table 1 from Glucagon-Like Peptide-1
Description
Their benefits now extend well beyond glycemic control and weight loss, with growing evidence supporting their use in the management of steatosis liver disease, obstructive sleep apnea, cardiovascular disease, and chronic kidney disease

Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life

Multiple Once-Daily Dose Pharmacodynamics The pharmacodynamics of TOUJEO after 8 days of daily injection was evaluated in 30 patients with type 1 diabetes

Acute hyperglycemia is known to delay gastric emptying, disrupt antro-pyloric motility and blunt the response to prokinetic medications

There is no established direct causal link between GLP-1 receptor agonists and erectile dysfunction based on current clinical evidence

Most formulations from licensed 503A compounding pharmacies need refrigeration between 36F and 46F (2C to 8C), similar to insulin storage protocols
